Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
16
1
0
0
CONCERT PHARMACEUTICALS INC
Share · US2060221056 · CNCE · A1XEAC (XNMS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CONCERT PHARMACEUTICALS INC
Analyst Grade Summary
No Price
Invested Funds
The following funds have invested in CONCERT PHARMACEUTICALS INC:
Fund | Vol. in million 3,61 | Percentage (%) 0,0085 % |
Company Profile for CONCERT PHARMACEUTICALS INC Share
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Company Data
Name CONCERT PHARMACEUTICALS INC
Company Concert Pharmaceuticals, Inc.
Symbol CNCE
Website
https://www.concertpharma.com
Primary Exchange 
NASDAQ/NMS (GLOBAL MARKET)
NASDAQ/NMS (GLOBAL MARKET)
WKN A1XEAC
ISIN US2060221056
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Roger D. Tung
Country United States of America
Currency USD
Employees 0,1 T
Address 65 Hayden Avenue, 02421 Lexington
IPO Date 2014-02-13
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | CNCE |
More Shares
Investors who hold CONCERT PHARMACEUTICALS INC also have the following shares in their portfolio:
